Which New Diagnostics for Tuberculosis, and When?
Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes...
Gespeichert in:
Veröffentlicht in: | The Journal of infectious diseases 2012-05, Vol.205 (suppl_2), p.S191-S198 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S198 |
---|---|
container_issue | suppl_2 |
container_start_page | S191 |
container_title | The Journal of infectious diseases |
container_volume | 205 |
creator | Cobelens, Frank van den Hof, Susan Pai, Madhukar Squire, S. Bertel Ramsay, Andrew Kimerling, Michael E. |
description | Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes place when limited evidence beyond test accuracy is available. There is a need to provide guidance to tuberculosis programs about which new diagnostics to scale up and how best to position them in diagnostic algorithms. To speed adoption of new diagnostics for tuberculosis, the policy recommendation process should be revised to consist of 2 steps: technical recommendation and programmatic recommendation. Technical recommendation would follow the GRADE process and be based on accuracy with limited cost and feasibility data, while programmatic recommendation would include patient-important outcomes, cost-effectiveness when implemented under routine conditions, and factors critical to successful scale-up. The evidence for both steps should be systematically collected, but each requires different study designs. |
doi_str_mv | 10.1093/infdis/jis188 |
format | Article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1018859689</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>23217124</jstor_id><sourcerecordid>23217124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c354t-850fc2d1efbf3c7a664b11731329f5c2b9b31fa80eb45c7a98d10dc25efe2d353</originalsourceid><addsrcrecordid>eNpF0L1PwzAQBXALgWgpjIygjAyE-uzYsSdUlU-pgqWoY5Q4NnWVJsWXCPHfE5QC0w3vpyfdI-Qc6A1Qzae-dqXH6cYjKHVAxiB4GksJ_JCMKWUsBqX1iJwgbiilCZfpMRkxlqQyBTkmsFp7s45e7Gd05_P3usHWG4xcE6JlV9hguqpBj9dRXpfRam3r21Ny5PIK7dn-Tsjbw_1y_hQvXh-f57NFbLhI2lgJ6gwrwbrCcZPmUiYFQMqBM-2EYYUuOLhcUVskos-1KoGWhgnrLCu54BNyNfTuQvPRWWyzrUdjqyqvbdNhBrR_WGipdE_jgZrQIAbrsl3w2zx89Sj7WSkbVsqGlXp_ua_uiq0t__TvLD24GMAG2yb855xBCizh39dWbY4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1018859689</pqid></control><display><type>article</type><title>Which New Diagnostics for Tuberculosis, and When?</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Cobelens, Frank ; van den Hof, Susan ; Pai, Madhukar ; Squire, S. Bertel ; Ramsay, Andrew ; Kimerling, Michael E.</creator><creatorcontrib>Cobelens, Frank ; van den Hof, Susan ; Pai, Madhukar ; Squire, S. Bertel ; Ramsay, Andrew ; Kimerling, Michael E. ; Evidence for Scale-up Group</creatorcontrib><description>Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes place when limited evidence beyond test accuracy is available. There is a need to provide guidance to tuberculosis programs about which new diagnostics to scale up and how best to position them in diagnostic algorithms. To speed adoption of new diagnostics for tuberculosis, the policy recommendation process should be revised to consist of 2 steps: technical recommendation and programmatic recommendation. Technical recommendation would follow the GRADE process and be based on accuracy with limited cost and feasibility data, while programmatic recommendation would include patient-important outcomes, cost-effectiveness when implemented under routine conditions, and factors critical to successful scale-up. The evidence for both steps should be systematically collected, but each requires different study designs.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jis188</identifier><identifier>PMID: 22476716</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Algorithms ; Antitubercular Agents - therapeutic use ; Bacteriological Techniques - economics ; Bacteriological Techniques - methods ; Bacteriological Techniques - trends ; Developing Countries ; Diagnostic methods ; Diagnostic tools ; Drug resistance ; Evaluation Studies as Topic ; Health outcomes ; Health Policy ; Humans ; Multidrug resistant tuberculosis ; Mycobacterium tuberculosis ; Recommendations ; Tuberculosis ; Tuberculosis - diagnosis ; Tuberculosis - drug therapy ; Tuberculosis control ; VIEWPOINT ARTICLE ; World Health Organization</subject><ispartof>The Journal of infectious diseases, 2012-05, Vol.205 (suppl_2), p.S191-S198</ispartof><rights>Copyright © 2012 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c354t-850fc2d1efbf3c7a664b11731329f5c2b9b31fa80eb45c7a98d10dc25efe2d353</citedby><cites>FETCH-LOGICAL-c354t-850fc2d1efbf3c7a664b11731329f5c2b9b31fa80eb45c7a98d10dc25efe2d353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/23217124$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/23217124$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>315,782,786,805,27931,27932,58024,58257</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22476716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cobelens, Frank</creatorcontrib><creatorcontrib>van den Hof, Susan</creatorcontrib><creatorcontrib>Pai, Madhukar</creatorcontrib><creatorcontrib>Squire, S. Bertel</creatorcontrib><creatorcontrib>Ramsay, Andrew</creatorcontrib><creatorcontrib>Kimerling, Michael E.</creatorcontrib><creatorcontrib>Evidence for Scale-up Group</creatorcontrib><title>Which New Diagnostics for Tuberculosis, and When?</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes place when limited evidence beyond test accuracy is available. There is a need to provide guidance to tuberculosis programs about which new diagnostics to scale up and how best to position them in diagnostic algorithms. To speed adoption of new diagnostics for tuberculosis, the policy recommendation process should be revised to consist of 2 steps: technical recommendation and programmatic recommendation. Technical recommendation would follow the GRADE process and be based on accuracy with limited cost and feasibility data, while programmatic recommendation would include patient-important outcomes, cost-effectiveness when implemented under routine conditions, and factors critical to successful scale-up. The evidence for both steps should be systematically collected, but each requires different study designs.</description><subject>Algorithms</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Bacteriological Techniques - economics</subject><subject>Bacteriological Techniques - methods</subject><subject>Bacteriological Techniques - trends</subject><subject>Developing Countries</subject><subject>Diagnostic methods</subject><subject>Diagnostic tools</subject><subject>Drug resistance</subject><subject>Evaluation Studies as Topic</subject><subject>Health outcomes</subject><subject>Health Policy</subject><subject>Humans</subject><subject>Multidrug resistant tuberculosis</subject><subject>Mycobacterium tuberculosis</subject><subject>Recommendations</subject><subject>Tuberculosis</subject><subject>Tuberculosis - diagnosis</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis control</subject><subject>VIEWPOINT ARTICLE</subject><subject>World Health Organization</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0L1PwzAQBXALgWgpjIygjAyE-uzYsSdUlU-pgqWoY5Q4NnWVJsWXCPHfE5QC0w3vpyfdI-Qc6A1Qzae-dqXH6cYjKHVAxiB4GksJ_JCMKWUsBqX1iJwgbiilCZfpMRkxlqQyBTkmsFp7s45e7Gd05_P3usHWG4xcE6JlV9hguqpBj9dRXpfRam3r21Ny5PIK7dn-Tsjbw_1y_hQvXh-f57NFbLhI2lgJ6gwrwbrCcZPmUiYFQMqBM-2EYYUuOLhcUVskos-1KoGWhgnrLCu54BNyNfTuQvPRWWyzrUdjqyqvbdNhBrR_WGipdE_jgZrQIAbrsl3w2zx89Sj7WSkbVsqGlXp_ua_uiq0t__TvLD24GMAG2yb855xBCizh39dWbY4</recordid><startdate>20120515</startdate><enddate>20120515</enddate><creator>Cobelens, Frank</creator><creator>van den Hof, Susan</creator><creator>Pai, Madhukar</creator><creator>Squire, S. Bertel</creator><creator>Ramsay, Andrew</creator><creator>Kimerling, Michael E.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120515</creationdate><title>Which New Diagnostics for Tuberculosis, and When?</title><author>Cobelens, Frank ; van den Hof, Susan ; Pai, Madhukar ; Squire, S. Bertel ; Ramsay, Andrew ; Kimerling, Michael E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c354t-850fc2d1efbf3c7a664b11731329f5c2b9b31fa80eb45c7a98d10dc25efe2d353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Algorithms</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Bacteriological Techniques - economics</topic><topic>Bacteriological Techniques - methods</topic><topic>Bacteriological Techniques - trends</topic><topic>Developing Countries</topic><topic>Diagnostic methods</topic><topic>Diagnostic tools</topic><topic>Drug resistance</topic><topic>Evaluation Studies as Topic</topic><topic>Health outcomes</topic><topic>Health Policy</topic><topic>Humans</topic><topic>Multidrug resistant tuberculosis</topic><topic>Mycobacterium tuberculosis</topic><topic>Recommendations</topic><topic>Tuberculosis</topic><topic>Tuberculosis - diagnosis</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis control</topic><topic>VIEWPOINT ARTICLE</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cobelens, Frank</creatorcontrib><creatorcontrib>van den Hof, Susan</creatorcontrib><creatorcontrib>Pai, Madhukar</creatorcontrib><creatorcontrib>Squire, S. Bertel</creatorcontrib><creatorcontrib>Ramsay, Andrew</creatorcontrib><creatorcontrib>Kimerling, Michael E.</creatorcontrib><creatorcontrib>Evidence for Scale-up Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cobelens, Frank</au><au>van den Hof, Susan</au><au>Pai, Madhukar</au><au>Squire, S. Bertel</au><au>Ramsay, Andrew</au><au>Kimerling, Michael E.</au><aucorp>Evidence for Scale-up Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Which New Diagnostics for Tuberculosis, and When?</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2012-05-15</date><risdate>2012</risdate><volume>205</volume><issue>suppl_2</issue><spage>S191</spage><epage>S198</epage><pages>S191-S198</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes place when limited evidence beyond test accuracy is available. There is a need to provide guidance to tuberculosis programs about which new diagnostics to scale up and how best to position them in diagnostic algorithms. To speed adoption of new diagnostics for tuberculosis, the policy recommendation process should be revised to consist of 2 steps: technical recommendation and programmatic recommendation. Technical recommendation would follow the GRADE process and be based on accuracy with limited cost and feasibility data, while programmatic recommendation would include patient-important outcomes, cost-effectiveness when implemented under routine conditions, and factors critical to successful scale-up. The evidence for both steps should be systematically collected, but each requires different study designs.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>22476716</pmid><doi>10.1093/infdis/jis188</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-1899 |
ispartof | The Journal of infectious diseases, 2012-05, Vol.205 (suppl_2), p.S191-S198 |
issn | 0022-1899 1537-6613 |
language | eng |
recordid | cdi_proquest_miscellaneous_1018859689 |
source | MEDLINE; JSTOR Archive Collection A-Z Listing; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
subjects | Algorithms Antitubercular Agents - therapeutic use Bacteriological Techniques - economics Bacteriological Techniques - methods Bacteriological Techniques - trends Developing Countries Diagnostic methods Diagnostic tools Drug resistance Evaluation Studies as Topic Health outcomes Health Policy Humans Multidrug resistant tuberculosis Mycobacterium tuberculosis Recommendations Tuberculosis Tuberculosis - diagnosis Tuberculosis - drug therapy Tuberculosis control VIEWPOINT ARTICLE World Health Organization |
title | Which New Diagnostics for Tuberculosis, and When? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T20%3A44%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Which%20New%20Diagnostics%20for%20Tuberculosis,%20and%20When?&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Cobelens,%20Frank&rft.aucorp=Evidence%20for%20Scale-up%20Group&rft.date=2012-05-15&rft.volume=205&rft.issue=suppl_2&rft.spage=S191&rft.epage=S198&rft.pages=S191-S198&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jis188&rft_dat=%3Cjstor_proqu%3E23217124%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1018859689&rft_id=info:pmid/22476716&rft_jstor_id=23217124&rfr_iscdi=true |